drugset / Trial / NCT07152782
T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
RandomizedParallel-groupOpen-labelTreatment
Summary
A phase II, open-label, multicenter, randomized controlled trial exploring the efficacy and safety of Trastuzumab Deruxtecan combined with or without Neratinib in HER2-positive breast cancer with brain metastasis
Timeline
- Start
- 2025-11
- Primary completion
- 2027-11
- Completion
- 2029-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neratinib | Small molecule | 200 mg | Oral |
| Subject | Trastuzumab deruxtecan | Monoclonal antibody | 5.4 mg/kg | Intravenous |